Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 12, 2025 08:00 ET | Source: PharmaTher Holdings Ltd.

PharmaTher Provides Update on FDA New Drug Application for Ketamine

TORONTO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company seeking FDA approval for ketamine,...
November 26, 2024 08:00 ET | Source: PharmaTher Holdings Ltd.

PharmaTher Announces Update on FDA New Drug Application for Ketamine

FDA provided preliminary responses to questions contained in the clarification only post-CRL meeting scheduled for December 2, 2024PharmaTher has decided to cancel the meeting as the FDA preliminary...
November 19, 2024 08:00 ET | Source: PharmaTher Holdings Ltd.

PharmaTher Announces Update on FDA New Drug Application for Ketamine

FDA granted a post-complete letter clarification meeting scheduled for December 2, 2024 Company initiated activities to address the deficiencies cited in the CRL TORONTO, Nov. 19, 2024 (GLOBE...
November 13, 2024 08:00 ET | Source: PharmaTher Holdings Ltd.

PharmaTher Announces Post Complete Response Letter Clarification Meeting Request Granted from the FDA for Ketamine Abbreviated New Drug Application

TORONTO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, today announced that the Company...
September 27, 2023 07:30 ET | Source: PharmaTher Holdings Ltd.

PharmaTher Announces FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX™ (Ketamine)

FDA assigns GDUFA goal date of April 29, 2024 Milestone builds upon PharmaTher’s commitment toward unlocking the potential of ketamine for unmet medical needs TORONTO, Sept. 27, 2023 (GLOBE...